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Objective: To gain insight into selective transmission of HIV-I from
mothers to infants, analyses of local chemokine, cytokine and chemokine
receptor expression in placenta from transmitting and non-transmitting
women were performed.
Methods: Placentas samples were obtained from 13 HIV-infected women
including to from non-transmitting women and three from transmitting
women. Itl situ imaging was used to study expression of chemokines,
cytokines and chemokine receptors at the single cell level in immunohisto-
chemically stained sections. Simultaneous immunoftorescence itl situ hybri-
disation for HIV-l gag-pol mRNA was performed to confirm selective
utilisation of chemokine receptors in all sections.
Results: Itl situ imaging ofimmunohistochemically stained placenta sections
and R T-PCR demonstrated 3-fold increase in CCR5: CXCR4 expression
ratio in placentas from transmitting women compared to placentas from
non-transmitting women. This chemokine receptor repertoire is consistent
with an upregulation of IL-4 and IL-I0 expression in placentas from non-
transmitting placentas compared to transmitting placentas. Ttl situ imaging
demonstrated that CCR5 and CXCR4 are expressed on placental macro-
phages and lymphocytes but not in trophoblasts. Rantes expression in non-
transmitting women was, furthermore, lower compared to normal controls.
Simultaneous immunoftorescence in situ hybridisation for HIV-l gag-pol
mRNA revealed that HIV-l infects primarily CXCR4 expressing cells in
placentas from non-transmitting women. While both CXCR4 and CCR5
expressing cells were infected in transmitting women.
Conclusion: These data are consistent with transmission of predominantly
nonsyncytium inducing (NSI) HIV-l isolates that use CCR5 as co-receptor.
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Objectives: To assess whether a malfunction in granule mediated cytotoxic
T-cell (CTL) mediated immunity is involved in establishing HIV latency in
lymphoid tissues.
Methods: lymphoid tissue and peripheral blood mononuclear cells
(PBMCs) from HIV infected patients were immunohistochemicaolly
stained for granzyme A and perforin proteins at the single cell level and
quantified by acquired computer imaging analysis. The results were com-
pared to perforin and granzyme A expression in lymphoid tissue obtained
from patients with tonsillar hyperplasia (HT) and patients with EBVinfec-
tion.
Results: Perforin and granzyme A expression was significancly upregulated
in patients with infectious mononucleosis in comparison to the negative
controls (HT tissue). In the HIV infected tissues granzyme A was also
upregulated in comparison to the negative controls. However. unlike the
EBV infected tissues where both perforin and granzyme A were expressed in
equal amounts, in the HIV infected tissue there was 10 times more granzyme
A present than perforin. This same dissociation between perforin and
granzyme A was not observed in the HIV infected PBMCs.
Conclusions: The relative lack of perforin expression in HIV infected
lymphoid tissues may be one way that HIV is inhibiting HIV specific
CTls from eliminating virally infected cells.
IMo031 A three-year monitoring of substitution of HIV
protease Inhibitors {PI} In clinical practice: Frequency, features,
and 12-month outcome
R. Manfredi, F. Chiodo
Department of Infectious Diseases, University ofBologna, Bologna, Italy
Objective: To assess the frequency, features, and outcome ofswitch of HIV
PI in clinical practice.
Methods: 942 patients (p) who received saquinavir (SQV), indinavir (IDV)
or ritonavir (RTV) since 1996. and nelfinavir (NFV) since 1998, were
followed. An increase of plasma HIV-RNA levels ~ 1.0 logto, and/or a
viremia persistingly > 5 x Ilf copies/mL, and/or a drop of CD4 + cell
count ~ lSOllll or ~20%, and/or a CD4+ count steadily < loo/ill after
~6 months of therapy. defined treatment failure. Signs, symptoms, and/or
laboratory examinations showing possibly related adverse events or toxicity,
accounted for poor tolerability. One year after treatment modification, viral
suppression or a decrease ofviremia ~ 1 logl0, and/or a rise ~ 100 cellslill
or ~15% of CD4+ count, documented a favorable efficacy, while the
ability to continue the newly introduced regimen was considered as a
positive tolerability outcome.
Results: During the study period, 381 p of 942 (40.4%) experienced ~1
change of PI (414 overall changes), with RTV borne by the highest
frequency of changes. In 191 cases (46.1 %) the switch was due to poor
tolerability, with SQV significantly better tolerated than RTV, NFV and
IDV, and IDV better tolerated than RTV (p < .001); one year after the
introduction of a novel regimen, in 161 cases of 191 (84.3%) a favorable
tolerability was seen, in absence of significant differences related to both
prior and subsequent drug choices. Therapeutic failure was ofconcern in the
remaining 223 cases. with SQV interested by greater frequency and earlier
occurrence of failure compared with those oflDV and RTV (p < .001),
although the subsequent switch led to a significantly better 12-month
outcome, compared with that ofp failing other PI (p < .001). A comparable
frequency offailure was found with R TV, mv and NFV, but NFV had a
significantly shorter time to change (p < .001), and a tendency to a less
favorable outcome, vs those ofRTV and lDV. IDV and R TV presented a
longer time to failure compared with SQV and NFV (p < .001), but p
discontinuing lDV or R TV due to poor efficacy had a lower probability to
benefit from the switch.
n. changes (%)
n. changes/ failure/ with
discontinued n. patients intolerance time to change positive l-yr
p[ (%) ratio (months ± SO) outcome
SQV 98/279 (35.[) 9117 6.4 ± 2.3 89/98 (90.8)
RTV 93/148 (62.8) 21172 13.3 ± 4.9 83/93 (89.2)
[OV [85/598 (30.9) 98/87 [2.8 ± 4.4 120/185 (64.9)
NFV 38/89 (42.7) 13/25 5.9 ± 1.4 27/38 (71.1)
Conclusion: Resistance, poor compliance, and toxicity will increasingly
limit the efficacy and durability of PI. Considering the different features of
each PI. initial and subsequent therapeutic choices should balance expected
benefits and risks, in order to rationally exploit all available drug resources.
IMo041 Hypolipidemic drugs in the treatment of
hypertriglyceridemia and hypercholesterolemia diagnosed in
patIents with HIV disease
R. Manfredi, F. Chiodo
Depar,ment of Infectious Di.eases, Utliversiry ofBologna, Bologna, Ilaly
Objective: To evaluate the role ofbezafibrate in the management oflipemia
in patients (p) with HIV disease.
Methods: HIV-infected p with high plasma triglyceride and/or cholesterol
levels (> 300 and 200 mg/dL, respectively) of ~6 months duration,
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Background: The use ofPI in HIV-infected patients has been associated with
a variety of metabolic abnormalities.
Methods: This cross-sectional study was undertaken to determine the
prevalence of lipid profile abnormalities in HIV-infected patients treated
with protease inhibitors (PI). All the patients were evaluated with anthro-
pometric measures, a complete hormonal profile, and a lipid profile includ-
ing total cholesterol (Chol), triglycerides, LDL-Chol, VLDL-Chol, HDt-
Chol, apolipoprotein A and B, glucose and insulin.
Results: One hundred and twenty men and 39 women with a mean age of
38.7 ± 8.6 ye:trs were studied. The mean time on PI therapy was 11.7 ± 5.8
months. Most of them (107,69%) were on indinavir. Only 9 patients had
clinical features of Iypodystrophy. Most patients (103, 64.8%) had unde-
tectable levels of viremia. The waist-hip ratio (WHR) was increased in 18
men (15%) and 11 women (28.2%). Abnormal increases of Chol were
present in 36 patients (22.6%), TG in 57 (35.8%), LDL-Chol in 31 (19.6%),
VLDL-Chol in 31 (19.6%), whereas decreases in HDL-Chol were found in
49.6% of men and 56.4% of women. Apo B was incre:tsed in 28.9% of
women, and 34.2% of men. Overall, 14 women (35.9%) and 23 men
(19.2%) had all the lipid parameters within the normal range (p = .05).
There was a positive correlation between WHR and TG level (r = .18, P =
.02), HDL-Chol (r = .32, P = .0001), and VLDL-Chol (r = .2, P = .01).
Conclusions: Protease-inhibitor therapy in HIV-infected patients is asso-
ciated with central obesity and a highly atherogenic lipid profile.
[Mo061 Stevens-Johnson syndrome induced by nevirapine:
Report of 2 cases
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Background: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN), and the SJS/TEN overlap syndrome (OS) are severe skin drug
reactions. We report 2 cases ofSJS induced by nevirapine (NVP).
Case reports: A SJS was diagnosed in a 39-year-old HIV-I infected man
(CD 4 = 81{mm3, viral load = 270,OOO{ml) 47 days after the initiation of
NVP, zidovudine and lamivudine. Medication withdrawal resulted in full
recovery, and reexposure with zidovudine, lamivudine and efavirenz was
well tolerated. In a 34-year-old HIV-1 infected man (CD4 = 150/mm3, viral
load = 10,OOO/ml) a SJS occurred 17 days after treatment onset with NVP,
lamivudine and zidovudine. The lesions resolved after treatment disconti-
nuation and administration of intravenous immunoglobulins. No relapse
was observed after reehallenging with zidovudine, lamivudine and indina-
vir.
Discussion: According to a MedIine rese:trch, only 4 eases of NVP-asso-
ciated SJS, TEN, or OS have been published. in clinical trials, NVP-induced
severe skin reactions occurred with a frequency of0.3%, and the incidence
estimated by the French Postmarketing Registry (Boehringer ingelheim
Pharmaceuticals) is 0.03%.
Condusion: Although rare, severe NVP-induced skin drag reactions may
occur even several weeks after treatment onset; the safety of the subsequent
use ofan alternative NNRn, as suggested by one ofour cases, needs further
confirmation.
P:1/1 - HIV treatment and side eects
[MoP1! Highly active antiretroviral therapy (HAARI'}-induced
metabolic abnormalities in HIV-lnfected patients
cholesterol and tryglyceride variation profile between two groups. The
virologic improvement ofthe subgroups ofpatients with high viral load was
similar in A and B arms. Opportunistic infections were: Arm A: 1 Kaposi's
sarcoma; group B: 2 Kaposi's sarcoma, 1 herpes zoster, I B limphoma.
Changes of treatment due to toxicity: 4 eases: 1 lactic acidosis (d4T), 1
polyneurophaty (ddI), 1 vomiting (IDV), 1 ALT/AST elevation (NVP).
Condusions: The virological and immunological efficacy was similar in
both groups. Both treatment regimens were well-tolerated, with little
repercussion in the patients' lipid profile. No differences were observed in
high viral load subgroups.
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occurring during treatment with protease inhibitors (PI) and unresponsive to
a hypolipidemic diet, received bezafibrate, 400 mg/day.
Results: 49 consecutive p out of ",,800 (6.1%) treated with PI since 2:9
months developed hypertriglyceridemia, with or without concurrent
hypercholesterolemia and hyperglycemia. Twenty-three p received ritona-
vir, 20 indinavir, and the remaining 6 p two combined or sequential PI, for a
mean period of12.9 ± 2.7 months. At the start ofbezafibrate treatment, no
significant difference of mean plasma triglyceride and cholesterol levels,
concurrent signs of lipodystrophy (found in 27 pl. and concomitant fasting
hyperglycemia (found in 9 p), were observed according to prior PI
treatment. Bezafibrate was administered for 2:6 months (and up to 15
months) and led to a reduction oftriglyceride and cholesterollevcls > 40%
and> 25% ofrespective baseline values, already obtained after the 6 months
(p < .(01), and maintained during the subsequent 6 months without
relevant modifications. Thirty-one p of 49 (63.3%) reached normal trigly-
ceride values « 172 mg/dL) after 6-9 months, and normal cholesterol and
glucose levels were obtained in all P with previously detected abnormalities,
while no relevant change of lipodystrophy was observed. No difference of
theupeuric response was detected during the follow-up according to the
underlying PI regimen, but in 4 P treated with ritonavir the persistence of
triglyeeridemia > 300 mg/dL beyond 6 months ofbezafibrate therapy, and
some concurrent drug-related ganrointestinal complaints, made PI switch
necessary. Bezafibrate, had a favorable tolerability profile: mild gastroen-
teric signs and symptoms were found in only 8.2% of 49 p.
Discussion: Metabolic abnormalities are increasingly found among HIV-
infected p receiving PI-containing anti-HIV therapy. so that frequent
monitoring of triglyceride and cholesterol levels is strongly recommended,
in order to provide dietary suggestions and hypolipidemic treatment. By
acting on hepatic synthesis of triglycerides and cholesterol, bezafibrate
demonstrates favorable efficacy and safety in the treatment of PI-related
lipemia.
IMoosl A open-label, randomized, comparative study of
Stavudine (d4l) + Oidan05ine (ddl) + Indlnavir (lOY) versus d4T +
ddl + Nevirapine (NVP) in treatment of HIV-infected naive
patients
]. M. Guardiola, P. Domingo, M. Sambeat. M. Fuste.]. Cadafalch,]. Ris,
]. Barrio. M. Gurgui, G. Vazquez
Sallt Pau Hospital, Barcelolla, Spaill
Objectives: The aim of the study was to find a more eFonomical, better
tolerated and more easily administered therapy with a combination of two
NRTI's with NVP.
Methods: A 32 week randomized study comparing the safety and activity of
d4T 40 mg ql2h + ddl400 mg q24h + NVP 200 mg q12h (arm A) vs d4T
+ ddI + mv 800 mg q8h (arm B) in 50 HIV-infected adults (73% males,
mean age 39.3 ± 17.8 years) who were treatment naIve with HIV RNA>
5000 copies/mL (Amplicor, Roche assay). The primary endpoints were
percentage ofpatients with < 200 and < 50 cp/mL HIV RNA, change from
baseline in plasma HIV RNA and CD4 cell count. Lipidic profiles and the
incidence of clinical events and treatment toxicity was analyzed. Moreover
we analyze a subgroup ofpatients with high viral load (> 100.000 cop/mL).
Results: Median entry HIV RNA and CD4 cell count were 5.2 log and 5.4
log; and 370 and 337 c/mm3 for group A (n = 26) and group B (n = 24)
respectively. Intent to treat analyses is: HIV RNA below < 200 cop/mL and
< 50 cop/mL is 72% and 51 %; and 71.3% and 50% for A and B groups
respectively. Changes from baseline in plasma HIV RNA and median
increase of CD4 cells/mm3 count were: -1.9 log and -1.5 log; and 223
and 166 for a A and B group re>pcetivdy. No differences were observed in
